691 related articles for article (PubMed ID: 25471040)
1. Estrogen and progesterone receptors in breast cancer.
Yip CH; Rhodes A
Future Oncol; 2014 Nov; 10(14):2293-301. PubMed ID: 25471040
[TBL] [Abstract][Full Text] [Related]
2. [Steroid receptors and breast carcinoma].
Pasić R; Dulbegović B; Softić D; Wittlif JL
Med Pregl; 1991; 44(1-2):48-51. PubMed ID: 1870463
[TBL] [Abstract][Full Text] [Related]
3. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
O'Connor SM; Beriwal S; Dabbs DJ; Bhargava R
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):268-72. PubMed ID: 20186046
[TBL] [Abstract][Full Text] [Related]
4. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
[TBL] [Abstract][Full Text] [Related]
5. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
7. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
8. Quantitative image analysis of estrogen and progesterone receptors as a prognostic tool for selecting breast cancer patients for therapy.
Castagnetta LA; Traina A; Liquori M; Marasà L; Amodio R; Di Falco M; Miele M; Rausa L; Carruba G
Anal Quant Cytol Histol; 1999 Feb; 21(1):59-62. PubMed ID: 10068777
[TBL] [Abstract][Full Text] [Related]
9. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
10. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
11. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status.
Tutera AM; Sellers TA; Potter JD; Drinkard CR; Wiesner GL; Folsom AR
Genet Epidemiol; 1996; 13(2):207-21. PubMed ID: 8722747
[TBL] [Abstract][Full Text] [Related]
12. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
Hefti MM; Hu R; Knoblauch NW; Collins LC; Haibe-Kains B; Tamimi RM; Beck AH
Breast Cancer Res; 2013; 15(4):R68. PubMed ID: 23971947
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X; Zhang P; Deng W; Oesterreich S; Lu Y; Mills GB; Lee AV
Mol Endocrinol; 2003 Apr; 17(4):575-88. PubMed ID: 12554765
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
18. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India.
Singh R; Gupta S; Pawar SB; Pawar RS; Gandham SV; Prabhudesai S
J Cancer Res Ther; 2014; 10(1):26-8. PubMed ID: 24762482
[TBL] [Abstract][Full Text] [Related]
20. Genotoxic factors associated with the development of receptor-negative breast cancer: potential role of the phenomenon of switching of estrogen effects.
Berstein LM; Tsyrlina EV; Poroshina TE; Levina VV; Vasilyev DA; Kovalenko IG; Semiglazov VF
Exp Oncol; 2006 Mar; 28(1):64-9. PubMed ID: 16614711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]